Long-term safety and effectiveness of growth hormone therapy in Korean children with growth disorders

5-year results of LG Growth Study

Young-Jun Rhie, Jae Ho Yoo, Jin Ho Choi, Hyun Wook Chae, Jae Hyun Kim, Sochung Chung, Il Tae Hwang, Choong Ho Shin, Eun Young Kim, Ho Seong Kim

Research output: Contribution to journalArticle

Abstract

Purpose The aim of this registry study was to analyze the long-term safety and effectiveness of recombinant human growth hormone (rhGH) in South Korean pediatric patients (2 years of age) with growth hormone deficiency GHD) of idiopathic or organic etiology, idiopathic short stature, Turner syndrome, small for gestational age and chronic renal failure. Methods The study patients were followed-up till two years after the epiphyseal closure, with visits scheduled every six months. The outcome measures included the incidence of adverse events (AEs, in particular, neoplasia, glucose intolerance and hypothyroidism), as well as height standard deviation score (Ht SDS) and annual height velocity. The results of the interim analysis of a 5-year accumulated data for 2,024 patients (7,342 patient-years, PY) are presented. Results A total of 14 neoplasms were diagnosed (191/100,000 PY); 7 out of 9 malignancies were recurrent craniopharyngioma found in patients with organic GHD. Seven cases of glucose intolerance (95/100,000 PY) and 22 cases of hypothyroidism (300/100,000 PY) were detected; about half of the cases (4 and 10 cases each) were considered to be related with rhGH treatment. Most of the growth-retarded patients showed continuous improvement in Ht SDS, with the most prominent effect observed within a year of treatment initiation. The beneficial effect of rhGH on Ht SDS gain was maintained for 2–4 years. Conclusions The incidence of AEs of interest in rhGH-treated patients was low, and most of the neoplasms were benign and/or non-related to rhGH. Most patients benefited from the therapy in terms of height increment.

Original languageEnglish
Article numbere0216927
JournalPLoS ONE
Volume14
Issue number5
DOIs
Publication statusPublished - 2019 May 1

Fingerprint

growth disorders
Growth Disorders
Human Growth Hormone
somatotropin
Growth Hormone
human growth
Safety
therapeutics
Growth
hypothyroidism
Glucose Intolerance
Therapeutics
Glucose
Hypothyroidism
Pediatrics
neoplasms
Neoplasms
small for gestational age
Craniopharyngioma
incidence

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Long-term safety and effectiveness of growth hormone therapy in Korean children with growth disorders : 5-year results of LG Growth Study. / Rhie, Young-Jun; Yoo, Jae Ho; Choi, Jin Ho; Chae, Hyun Wook; Kim, Jae Hyun; Chung, Sochung; Hwang, Il Tae; Shin, Choong Ho; Kim, Eun Young; Kim, Ho Seong.

In: PLoS ONE, Vol. 14, No. 5, e0216927, 01.05.2019.

Research output: Contribution to journalArticle

Rhie, Young-Jun ; Yoo, Jae Ho ; Choi, Jin Ho ; Chae, Hyun Wook ; Kim, Jae Hyun ; Chung, Sochung ; Hwang, Il Tae ; Shin, Choong Ho ; Kim, Eun Young ; Kim, Ho Seong. / Long-term safety and effectiveness of growth hormone therapy in Korean children with growth disorders : 5-year results of LG Growth Study. In: PLoS ONE. 2019 ; Vol. 14, No. 5.
@article{b9a9978c215d42d4a96738904a430881,
title = "Long-term safety and effectiveness of growth hormone therapy in Korean children with growth disorders: 5-year results of LG Growth Study",
abstract = "Purpose The aim of this registry study was to analyze the long-term safety and effectiveness of recombinant human growth hormone (rhGH) in South Korean pediatric patients (2 years of age) with growth hormone deficiency GHD) of idiopathic or organic etiology, idiopathic short stature, Turner syndrome, small for gestational age and chronic renal failure. Methods The study patients were followed-up till two years after the epiphyseal closure, with visits scheduled every six months. The outcome measures included the incidence of adverse events (AEs, in particular, neoplasia, glucose intolerance and hypothyroidism), as well as height standard deviation score (Ht SDS) and annual height velocity. The results of the interim analysis of a 5-year accumulated data for 2,024 patients (7,342 patient-years, PY) are presented. Results A total of 14 neoplasms were diagnosed (191/100,000 PY); 7 out of 9 malignancies were recurrent craniopharyngioma found in patients with organic GHD. Seven cases of glucose intolerance (95/100,000 PY) and 22 cases of hypothyroidism (300/100,000 PY) were detected; about half of the cases (4 and 10 cases each) were considered to be related with rhGH treatment. Most of the growth-retarded patients showed continuous improvement in Ht SDS, with the most prominent effect observed within a year of treatment initiation. The beneficial effect of rhGH on Ht SDS gain was maintained for 2–4 years. Conclusions The incidence of AEs of interest in rhGH-treated patients was low, and most of the neoplasms were benign and/or non-related to rhGH. Most patients benefited from the therapy in terms of height increment.",
author = "Young-Jun Rhie and Yoo, {Jae Ho} and Choi, {Jin Ho} and Chae, {Hyun Wook} and Kim, {Jae Hyun} and Sochung Chung and Hwang, {Il Tae} and Shin, {Choong Ho} and Kim, {Eun Young} and Kim, {Ho Seong}",
year = "2019",
month = "5",
day = "1",
doi = "10.1371/journal.pone.0216927",
language = "English",
volume = "14",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

TY - JOUR

T1 - Long-term safety and effectiveness of growth hormone therapy in Korean children with growth disorders

T2 - 5-year results of LG Growth Study

AU - Rhie, Young-Jun

AU - Yoo, Jae Ho

AU - Choi, Jin Ho

AU - Chae, Hyun Wook

AU - Kim, Jae Hyun

AU - Chung, Sochung

AU - Hwang, Il Tae

AU - Shin, Choong Ho

AU - Kim, Eun Young

AU - Kim, Ho Seong

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Purpose The aim of this registry study was to analyze the long-term safety and effectiveness of recombinant human growth hormone (rhGH) in South Korean pediatric patients (2 years of age) with growth hormone deficiency GHD) of idiopathic or organic etiology, idiopathic short stature, Turner syndrome, small for gestational age and chronic renal failure. Methods The study patients were followed-up till two years after the epiphyseal closure, with visits scheduled every six months. The outcome measures included the incidence of adverse events (AEs, in particular, neoplasia, glucose intolerance and hypothyroidism), as well as height standard deviation score (Ht SDS) and annual height velocity. The results of the interim analysis of a 5-year accumulated data for 2,024 patients (7,342 patient-years, PY) are presented. Results A total of 14 neoplasms were diagnosed (191/100,000 PY); 7 out of 9 malignancies were recurrent craniopharyngioma found in patients with organic GHD. Seven cases of glucose intolerance (95/100,000 PY) and 22 cases of hypothyroidism (300/100,000 PY) were detected; about half of the cases (4 and 10 cases each) were considered to be related with rhGH treatment. Most of the growth-retarded patients showed continuous improvement in Ht SDS, with the most prominent effect observed within a year of treatment initiation. The beneficial effect of rhGH on Ht SDS gain was maintained for 2–4 years. Conclusions The incidence of AEs of interest in rhGH-treated patients was low, and most of the neoplasms were benign and/or non-related to rhGH. Most patients benefited from the therapy in terms of height increment.

AB - Purpose The aim of this registry study was to analyze the long-term safety and effectiveness of recombinant human growth hormone (rhGH) in South Korean pediatric patients (2 years of age) with growth hormone deficiency GHD) of idiopathic or organic etiology, idiopathic short stature, Turner syndrome, small for gestational age and chronic renal failure. Methods The study patients were followed-up till two years after the epiphyseal closure, with visits scheduled every six months. The outcome measures included the incidence of adverse events (AEs, in particular, neoplasia, glucose intolerance and hypothyroidism), as well as height standard deviation score (Ht SDS) and annual height velocity. The results of the interim analysis of a 5-year accumulated data for 2,024 patients (7,342 patient-years, PY) are presented. Results A total of 14 neoplasms were diagnosed (191/100,000 PY); 7 out of 9 malignancies were recurrent craniopharyngioma found in patients with organic GHD. Seven cases of glucose intolerance (95/100,000 PY) and 22 cases of hypothyroidism (300/100,000 PY) were detected; about half of the cases (4 and 10 cases each) were considered to be related with rhGH treatment. Most of the growth-retarded patients showed continuous improvement in Ht SDS, with the most prominent effect observed within a year of treatment initiation. The beneficial effect of rhGH on Ht SDS gain was maintained for 2–4 years. Conclusions The incidence of AEs of interest in rhGH-treated patients was low, and most of the neoplasms were benign and/or non-related to rhGH. Most patients benefited from the therapy in terms of height increment.

UR - http://www.scopus.com/inward/record.url?scp=85065912477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065912477&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0216927

DO - 10.1371/journal.pone.0216927

M3 - Article

VL - 14

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 5

M1 - e0216927

ER -